1. Home
  2. MRKR vs LRE Comparison

MRKR vs LRE Comparison

Compare MRKR & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • LRE
  • Stock Information
  • Founded
  • MRKR N/A
  • LRE 2001
  • Country
  • MRKR United States
  • LRE Japan
  • Employees
  • MRKR N/A
  • LRE N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • LRE
  • Sector
  • MRKR Health Care
  • LRE
  • Exchange
  • MRKR Nasdaq
  • LRE Nasdaq
  • Market Cap
  • MRKR 35.8M
  • LRE 29.9M
  • IPO Year
  • MRKR N/A
  • LRE 2023
  • Fundamental
  • Price
  • MRKR $3.10
  • LRE $2.20
  • Analyst Decision
  • MRKR Strong Buy
  • LRE
  • Analyst Count
  • MRKR 1
  • LRE 0
  • Target Price
  • MRKR $19.00
  • LRE N/A
  • AVG Volume (30 Days)
  • MRKR 26.1K
  • LRE 45.5K
  • Earning Date
  • MRKR 11-14-2024
  • LRE 01-01-0001
  • Dividend Yield
  • MRKR N/A
  • LRE N/A
  • EPS Growth
  • MRKR N/A
  • LRE N/A
  • EPS
  • MRKR N/A
  • LRE 0.29
  • Revenue
  • MRKR $5,395,849.00
  • LRE $117,804,154.00
  • Revenue This Year
  • MRKR $35.94
  • LRE N/A
  • Revenue Next Year
  • MRKR N/A
  • LRE N/A
  • P/E Ratio
  • MRKR N/A
  • LRE $7.44
  • Revenue Growth
  • MRKR 79.04
  • LRE 8.82
  • 52 Week Low
  • MRKR $2.44
  • LRE $1.19
  • 52 Week High
  • MRKR $6.16
  • LRE $13.76
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 42.91
  • LRE 61.43
  • Support Level
  • MRKR $2.91
  • LRE $2.11
  • Resistance Level
  • MRKR $3.25
  • LRE $2.29
  • Average True Range (ATR)
  • MRKR 0.38
  • LRE 0.11
  • MACD
  • MRKR -0.11
  • LRE -0.00
  • Stochastic Oscillator
  • MRKR 17.72
  • LRE 68.97

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

Share on Social Networks: